预约演示
更新于：2026-08-06
TQC-3721
更新于：2026-08-06
概要
基本信息
药物类型 小分子化药 |
别名 TQC 3721、TQC-3721、TQC3721 |
作用方式 抑制剂 |
作用机制 PDE3抑制剂(磷酸二酯酶3抑制剂)、PDE4抑制剂(磷酸二酯酶4抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评突破性疗法 (中国) |
登录后查看时间轴
关联
11
项与 TQC-3721 相关的临床试验NCT07464587
Evaluation of Safety Profile in a Cohort Study of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07252908
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Inhalation Powder in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07147946
Evaluation of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial on the Efficacy and Safety of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
100 项与 TQC-3721 相关的临床结果
登录后查看更多信息
100 项与 TQC-3721 相关的转化医学
登录后查看更多信息
100 项与 TQC-3721 相关的专利（医药）
登录后查看更多信息
2
项与 TQC-3721 相关的文献（医药）2026-06-01CHEST
TQC3721
作者: Cazzola, Mario ; Matera, Maria Gabriella
2026-06-01CHEST
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II)
Article
作者: Yu, Ding ; Yu, Fa-Ming ; Yang, Ling ; Ma, Xiu-Qin ; Luo, Zhu ; Wu, Li-Qin ; Min, Ling-Feng ; Xiao, Zu-Ke ; Chen, Chao ; Liu, Dong ; Yuan, Bo ; Li, Wei-Min ; Qiu, Rong ; Li, Wei-Guo ; He, Li-Xiu ; Liu, Xun-Chao ; Wang, Tao ; Luo, Xiao-Bin ; Li, Xiao-Hua ; Zhang, Wei-Hua ; Dai, Ran-Ran ; Cao, Jie ; Liu, Xiao-Ju ; Jiang, Jian-Zhong
BACKGROUND:
Dual phosphodiesterase (PDE) 3 and 4 inhibitors have emerged as a novel therapeutic strategy for COPD, but their applicability remains limited to specific treatment contexts. To our knowledge, TQC3721 is a novel inhaled dual PDE3 and PDE4 inhibitor with synergistic bronchodilator and antiinflammatory effects.
RESEARCH QUESTION:
Does TQC3721 improve lung function and symptoms in patients with COPD receiving background therapy with single or dual long-acting bronchodilators?
STUDY DESIGN AND METHODS:
This phase 2, randomized, double-anonymized, placebo-controlled trial (A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [PACER-II]) was conducted at 27 tertiary centers in China. Participants with after bronchodilator FEV1 30% to 70% of predicted and FEV1/FVC < 0.7 were enrolled and randomized 1:1:1 to receive TQC3721 (3 or 6 mg) or placebo twice daily for 4 weeks. The primary end point was change of peak FEV1 from baseline over 4 weeks.
RESULTS:
A total of 240 patients were randomized and treated, with 28.8% and 71.2% receiving concomitant long-acting muscarinic antagonists (LAMAs) or long-acting β2-agonists (LABAs)/LAMAs, respectively. These results show that TQC3721 significantly improved peak FEV1 at week 4 (3 mg group, 100 mL [95% CI, 41 to 159; P = .0011]; 6 mg group, 147 mL [95% CI, 93 to 201; P < .0001]) compared with placebo. Treatment with 6 mg TQC3721 significantly improved average FEV1 area under the curve at 0 to 12 hours (87 mL; 95% CI, 43 to 131; P < .0001) and symptoms (St George's Respiratory Questionnaire score, -5.09; 95% CI, -8.44 to -1.74; P = .0031) vs placebo. Improvement of peak FEV1 at week 4 in the LAMA (239 mL; 95% CI, 130 to 348; P < .0001) and LABA/LAMA (109 mL; 95% CI, 47 to 170; P = .0006) subgroups was superior to placebo following treatment with 6 mg TQC3721. The safety profile of TQC3721 was similar to that of placebo.
INTERPRETATION:
Our results show that TQC3721 significantly improved lung function and symptoms compared with placebo in patients with COPD receiving concomitant single or dual long-acting bronchodilators, with good tolerability. The study supports further development of TQC3721 in COPD.
CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov; No.: NCT06527144; URL: www.
CLINICALTRIALS:
gov.
390
项与 TQC-3721 相关的新闻（医药）2026-08-03
100 项与 TQC-3721 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度慢性阻塞性肺疾病 | 临床3期 | 中国 | 2025-08-06 | |
| 严重慢性阻塞性肺疾病 | 临床3期 | 中国 | 2025-08-06 | |
| 哮喘 | 临床1期 | 中国 | 2021-10-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 240 | TQC3721 (3mg) | 鹹鏇鬱廠襯憲夢顧鹽齋(選選積範餘齋衊鹹醖鏇) = 願觸齋膚鑰醖壓膚廠繭 遞廠齋範齋遞製繭繭範 (遞範齋醖齋網鹹憲憲鬱, 144 ~ 244) | 积极 | 2025-09-27 | ||
TQC3721 (6mg) | 鹹鏇鬱廠襯憲夢顧鹽齋(選選積範餘齋衊鹹醖鏇) = 鹽築築繭獵積簾繭鏇壓 遞廠齋範齋遞製繭繭範 (遞範齋醖齋網鹹憲憲鬱, 196 ~ 286) 更多 | ||||||
临床1期 | - | 64 | 夢繭憲壓餘鑰遞窪鏇餘(積簾製觸積廠廠廠襯遞) = 1 subject experienced a grade 2 AE of anemia 築鏇膚衊衊淵積製憲壓 (鹹構餘顧鬱壓餘選憲遞 ) 更多 | 积极 | 2024-09-07 | ||
临床2期 | 75 | 獵餘鬱鑰構構壓簾製鑰(衊範糧廠蓋遞廠繭襯願) = 膚蓋顧壓構獵觸糧糧鏇 襯繭鹹廠蓋鹹鏇繭淵鹹 (餘夢壓壓鹹鏇積獵獵廠 ) 更多 | 积极 | 2024-01-01 | |||
安慰剂 | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用